异基因造血干细胞移植可克服急性髓系白血病患者DNMT3AmutNPM1mutFLT3-ITDmut的不良预后：中国现实世界多中心分析

IF 3.9 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Frontiers of Medicine Pub Date : 2024-12-07 DOI:10.1007/s11684-024-1091-5

Wenxuan Huo, Yifan Shen, Jiayu Huang, Yang Yang, Shuang Fan, Xiaosu Zhao, Qi Wen, Luxiang Wang, Chuanhe Jiang, Yang Cao, Xiaodong Mo, Yang Xu, Xiaoxia Hu

{"title":"异基因造血干细胞移植可克服急性髓系白血病患者DNMT3AmutNPM1mutFLT3-ITDmut的不良预后：中国现实世界多中心分析","authors":"Wenxuan Huo, Yifan Shen, Jiayu Huang, Yang Yang, Shuang Fan, Xiaosu Zhao, Qi Wen, Luxiang Wang, Chuanhe Jiang, Yang Cao, Xiaodong Mo, Yang Xu, Xiaoxia Hu","doi":"10.1007/s11684-024-1091-5","DOIUrl":null,"url":null,"abstract":"The cooccurrence of NPM1, FLT3-ITD, and DNMT3A mutations (i.e., triple mutation) is related to dismal prognosis in patients with acute myeloid leukemia (AML) receiving chemotherapy alone. In this multicenter retrospective cohort study, we aimed to identify whether allogeneic hematopoietic stem cell transplantation (allo-HSCT) could overcome the poor prognosis of DNMT3AmutNPM1mutFLT3-ITDmut AML across four transplant centers in China. Fifty-three patients with triple-mutated AML receiving allo-HSCT in complete remission were enrolled. The 1.5-year probabilities of relapse, leukemia-free survival, and overall survival after allo-HSCT were 11.9%, 80.3%, and 81.8%, respectively. Multivariate analysis revealed that more than one course of induction chemotherapy and allo-HSCT beyond CR1 were associated with poor survival. To our knowledge, this work is the largest study to explore the up-to-date undefined role of allo-HSCT in patients with triple-mutated AML. Our real-world data suggest that allo-HSCT could overcome the poor prognosis of DNMT3AmutNPM1mutFLT3-ITDmut in AML.","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Allogeneic hematopoietic stem cell transplantation could overcome the poor prognosis of DNMT3AmutNPM1mutFLT3-ITDmut in acute myeloid leukemia: real-world multicenter analysis in China.\",\"authors\":\"Wenxuan Huo, Yifan Shen, Jiayu Huang, Yang Yang, Shuang Fan, Xiaosu Zhao, Qi Wen, Luxiang Wang, Chuanhe Jiang, Yang Cao, Xiaodong Mo, Yang Xu, Xiaoxia Hu\",\"doi\":\"10.1007/s11684-024-1091-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The cooccurrence of NPM1, FLT3-ITD, and DNMT3A mutations (i.e., triple mutation) is related to dismal prognosis in patients with acute myeloid leukemia (AML) receiving chemotherapy alone. In this multicenter retrospective cohort study, we aimed to identify whether allogeneic hematopoietic stem cell transplantation (allo-HSCT) could overcome the poor prognosis of DNMT3AmutNPM1mutFLT3-ITDmut AML across four transplant centers in China. Fifty-three patients with triple-mutated AML receiving allo-HSCT in complete remission were enrolled. The 1.5-year probabilities of relapse, leukemia-free survival, and overall survival after allo-HSCT were 11.9%, 80.3%, and 81.8%, respectively. Multivariate analysis revealed that more than one course of induction chemotherapy and allo-HSCT beyond CR1 were associated with poor survival. To our knowledge, this work is the largest study to explore the up-to-date undefined role of allo-HSCT in patients with triple-mutated AML. Our real-world data suggest that allo-HSCT could overcome the poor prognosis of DNMT3AmutNPM1mutFLT3-ITDmut in AML.\",\"PeriodicalId\":12558,\"journal\":{\"name\":\"Frontiers of Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-12-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11684-024-1091-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11684-024-1091-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

NPM1、FLT3-ITD和DNMT3A突变（即三重突变）的同时发生与单纯化疗的急性髓性白血病（AML）患者预后不良有关。在这项多中心回顾性队列研究中，我们旨在确定中国四个移植中心的同种异体造血干细胞移植（alloo - hsct）是否可以克服DNMT3AmutNPM1mutFLT3-ITDmut AML的不良预后。53例完全缓解的三突变AML患者接受了同种异体造血干细胞移植。同种异体造血干细胞移植后的1.5年复发概率、无白血病生存率和总生存率分别为11.9%、80.3%和81.8%。多因素分析显示，超过一个疗程的诱导化疗和超过CR1的同种异体造血干细胞移植与较差的生存率相关。据我们所知，这项工作是迄今为止最大的一项研究，旨在探索同种异体造血干细胞移植在三突变AML患者中尚未明确的作用。我们的真实数据表明，同种异体造血干细胞移植可以克服AML中DNMT3AmutNPM1mutFLT3-ITDmut的不良预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Allogeneic hematopoietic stem cell transplantation could overcome the poor prognosis of DNMT3A^mutNPM1^mutFLT3-ITD^mut in acute myeloid leukemia: real-world multicenter analysis in China.

The cooccurrence of NPM1, FLT3-ITD, and DNMT3A mutations (i.e., triple mutation) is related to dismal prognosis in patients with acute myeloid leukemia (AML) receiving chemotherapy alone. In this multicenter retrospective cohort study, we aimed to identify whether allogeneic hematopoietic stem cell transplantation (allo-HSCT) could overcome the poor prognosis of DNMT3A^mutNPM1^mutFLT3-ITD^mut AML across four transplant centers in China. Fifty-three patients with triple-mutated AML receiving allo-HSCT in complete remission were enrolled. The 1.5-year probabilities of relapse, leukemia-free survival, and overall survival after allo-HSCT were 11.9%, 80.3%, and 81.8%, respectively. Multivariate analysis revealed that more than one course of induction chemotherapy and allo-HSCT beyond CR1 were associated with poor survival. To our knowledge, this work is the largest study to explore the up-to-date undefined role of allo-HSCT in patients with triple-mutated AML. Our real-world data suggest that allo-HSCT could overcome the poor prognosis of DNMT3A^mutNPM1^mutFLT3-ITD^mut in AML.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Frontiers of Medicine ONCOLOGYMEDICINE, RESEARCH & EXPERIMENTAL&-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

18.30

自引率

0.00%

发文量

800

期刊介绍： Frontiers of Medicine is an international general medical journal sponsored by the Ministry of Education of China. The journal is jointly published by the Higher Education Press and Springer. Since the first issue of 2010, this journal has been indexed in PubMed/MEDLINE. Frontiers of Medicine is dedicated to publishing original research and review articles on the latest advances in clinical and basic medicine with a focus on epidemiology, traditional Chinese medicine, translational research, healthcare, public health and health policies.